Align Technology (ALGN) offers dental technology products and manufactures Invisalign clear aligners. The company has a strong market presence and registered solid second-quarter results in July. In this article, we’ll look at Align Technology’s recent recommendations and target prices from Wall Street analysts.
On September 28, 16 analysts surveyed by Reuters tracked ALGN stock. Thirteen analysts (81%) rated ALGN stock as a “buy” or “strong buy.” Of these analysts, seven rated ALGN as a “strong buy” and six offered a “buy” rating. The remaining three analysts recommended a “hold” on ALGN stock. The chart above shows analysts’ recommendations for Align Technology since June 28.
On September 28, Align Technology stock had a consensus target price of $411.13 per share, implying a return potential of 5.4% based on its closing price of $389.97 on September 27.
On September 28, peers Dentsply Sirona (XRAY), Zimmer Biomet Holdings (ZBH), and Henry Schein (HSIC) had consensus target prices of $47.00, $136.39, and $82.56, respectively. These targets imply 12-month return potentials of 23.8%, 5.2%, and -3.1%, respectively.
Recent rating revisions and updates
Align Technology (ALGN) stock hasn’t received any recommendation updates since the stock was upgraded by several analysts in July. These upgrades followed the company’s strong second-quarter earnings results on July 25.
On July 31, Deutsche Bank raised its target price on ALGN stock from $250 to $370. The firm has a “hold” rating on the stock. On July 26, Barclays, Stifel, Leerink, Credit Suisse, and Berenberg also increased their target prices on ALGN stock.
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, historical data, and dividend information. Take a look!